Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Sponsor: Centessa Pharmaceuticals (UK) Limited
Summary
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities. While all conditions result in feeling sleepy, there are some differences in other common symptoms: * NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night. * NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy. * IH: People with IH feel tired during the day, even after sleeping a lot at night. They may sleep for long periods, take long naps, and find it hard to wake up. Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. ORX750 is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable ORX750 is in NT1, NT2, and IH, and learn about what the drug does to the body. Another goal of the study is to see if ORX750 can help people with NT1, NT2, and IH feel less sleepy and make other symptoms better.
Official title: A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2024-12-23
Completion Date
2025-12
Last Updated
2025-10-29
Healthy Volunteers
No
Interventions
ORX750
ORX750 capsule.
Placebo
ORX750 matching placebo capsule.
Locations (29)
Auburn, Alabama
Auburn, Alabama, United States
Chandler, Arizona
Chandler, Arizona, United States
Scottsdale, Arizona
Scottsdale, Arizona, United States
Long Beach, California
Long Beach, California, United States
Santa Ana, California
Santa Ana, California, United States
Brandon, Florida
Brandon, Florida, United States
Miami, Florida
Miami, Florida, United States
Miami, Florida
Miami, Florida, United States
Orlando, FL
Orlando, Florida, United States
Winter Park, Florida
Winter Park, Florida, United States
Atlanta, Georgia
Atlanta, Georgia, United States
Atlanta, Georgia
Atlanta, Georgia, United States
Riverdale, Georgia
Riverdale, Georgia, United States
New Orleans, Louisiana
New Orleans, Louisiana, United States
Newton, Massachusetts
Newton, Massachusetts, United States
Southfield, Michigan
Southfield, Michigan, United States
Sterling Heights, Michigan
Sterling Heights, Michigan, United States
Henderson, Nevada
Henderson, Nevada, United States
Denver, North Carolina
Denver, North Carolina, United States
Huntersville, North Carolina
Huntersville, North Carolina, United States
Cincinnati, Ohio
Cincinnati, Ohio, United States
Cleveland, OH
Cleveland, Ohio, United States
Dublin, Ohio
Dublin, Ohio, United States
Willow Grove, Pennsylvania
Willow Grove, Pennsylvania, United States
Columbia, South Carolina
Columbia, South Carolina, United States
North Charleston, South Carolina
North Charleston, South Carolina, United States
Austin, Texas
Austin, Texas, United States
San Antonio, Texas
San Antonio, Texas, United States
Toronto, Ontario
Toronto, Ontario, Canada